101367-16-2

Basic information

• Product Name: p-broMoxylylphthaliMide
• Synonyms: p-broMoxylylphthaliMide
• CAS NO: 101367-16-2
• Molecular Formula: C₁₆H₁₂BrNO₂
• Molecular Weight: 331.18392
• Mol File: 101367-16-2.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• CAS DataBase Reference: p-broMoxylylphthaliMide(CAS DataBase Reference)
• NIST Chemistry Reference: p-broMoxylylphthaliMide(101367-16-2)
• EPA Substance Registry System: p-broMoxylylphthaliMide(101367-16-2)

Safety Data

• Hazardous Substances Data: 101367-16-2(Hazardous Substances Data)

Upstream product

• 136918-14-4 phthalimide 
• 16473-35-1 4-(hydroxymethyl)benzyl chloride 
• 623-24-5 1,4-bis(bromomethyl)benzene 
• 439691-95-9 2-(4-(hydroxymethyl)benzyl)isoindoline-1,3-dione 
• 101207-45-8 2-(4-methylbenzyl)-1H-isoindol-1,3(2H)-dione 
• 1074-82-4 potassium phtalimide 

Downstream Products

• 1218909-37-5 [4-(1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)phenyl]acetonitrile 
• 101205-78-1 4-phthalimidomethylbenzyltriphenylphosphonium bromide 
• 1301740-40-8 1-{p-[bis(tert-butoxycarbonyl)guanidino]xylyl}-4,7-bis(tert-butoxycarbonyl)-1,4,7-triazacyclononane 
• 1301740-37-3 1-(p-aminoxylyl)-4,7-bis(tert-butoxycarbonyl)-1,4,7-triazacyclononane 
• 1301740-34-0 1-(p-phthalimidoxylyl)-4,7-bis(tert-butoxycarbonyl)-1,4,7-triazacyclononane 

Relevant articles and documents

Isoindoline-1,3-dione derivatives targeting cholinesterases: Design, synthesis and biological evaluation of potential anti-Alzheimer's agents

Alzheimer's disease is a fatal neurodegenerative disorder with a complex etiology. Because the available therapy brings limited benefits, the effective treatment for Alzheimer's disease remains the unmet challenge. Our aim was to develop a new series of donepezil-based compounds endowed with inhibitory properties against cholinesterases and β-amyloid aggregation. We designed the target compounds as dual binding site acetylcholinesterase inhibitors with N-benzylamine moiety interacting with the catalytic site of the enzyme and an isoindoline-1,3-dione fragment interacting with the peripheral anionic site of the enzyme. The results of pharmacological evaluation lead us to identify a compound 3b as the most potent and selective human acetylcholinesterase inhibitor (hAChE IC50 = 0.361 μM). Kinetic studies revealed that 3b inhibited acetylcholinesterase in non-competitive mode. The result of the parallel artificial membrane permeability assay for the blood-brain barrier indicated that the compound 3b would be able to cross the blood-brain barrier and reach its biological targets in the central nervous system. The selected compound 3b represents a potential lead structure for further development of anti-Alzheimer's agents.

Exploration of a Au(i)-mediated three-component reaction for the synthesis of DNA-tagged highly substituted spiroheterocycles

We demonstrate a Au(i)-mediated three-component reaction to DNA-tagged highly substituted 6-oxa-1,2-diazaspiro[4.4]nonanes from either DNA-coupled aldehydes, hydrazides, or alkynols. The choice of the starting material coupled to the DNA tag was critial for the purity of the product as the DNA-aldehyde conjugate yielded the purest products, whereas the alkynol- and hydrazide conjugates returned complex product mixtures. The reaction was compatible with thymine-, cytosine-, and, surprisingly, with adenine-DNA, while guanine-containing DNA strands were degraded under the reaction conditions.

PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THEREOF

The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation. The present disclosure provides compounds having hormone receptor antagonis